Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Partnerships 12
Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12
Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14
Pharm-Olam International Enters into Agreement with Infinity Pharma 15
Lead Discovery Center Partners with Infinity Pharma 16
Licensing Agreements 17
PellePharm Enters into Licensing Agreement with Infinity Pharma 17
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20
Equity Offering 21
Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 24
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 26
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 27
Infinity Pharmaceuticals Inc – Key Competitors 29
Infinity Pharmaceuticals Inc – Key Employees 30
Infinity Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
Nov 07, 2018: Bristol-Myers and Infinity partner for trial of opdivo and IPI-549 32
Financial Announcements 33
Nov 05, 2018: Infinity Pharmaceuticals provides company update and third quarter 2018 financial results 33
Aug 07, 2018: Infinity Pharmaceuticals provides company update and second quarter 2018 financial results 35
May 08, 2018: Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results 36
Nov 07, 2017: Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results 38
Aug 03, 2017: Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results 40
May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 43
Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 44
Corporate Communications 46
Aug 07, 2018: Infinity Pharmaceuticals appoints Samuel Agresta as Chief Medical Officer 46
Mar 08, 2018: Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board 47
Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 49
Jan 04, 2017: Infinity Announces Organizational Changes 50
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 11
Bristol-Myers Squibb and Infinity Pharma Enter into Collaboration Agreement 12
Arcus Biosciences and Infinity Pharma Enter into Clinical Collaboration Agreement 13
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 14
Pharm-Olam International Enters into Agreement with Infinity Pharma 15
Lead Discovery Center Partners with Infinity Pharma 16
PellePharm Enters into Licensing Agreement with Infinity Pharma 17
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 18
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 20
Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 21
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 23
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 24
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 26
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 27
Infinity Pharmaceuticals Inc, Key Competitors 29
Infinity Pharmaceuticals Inc, Key Employees 30
Infinity Pharmaceuticals Inc, Subsidiaries 31
List of Figures
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9